| Features: |
| Probiotics contain live bacteria the supplements the gastrointestinal flora. (Which can be affected from infection or antibiotics drugs.) Some studies have suggested that gut microbiota—including Bifidobacterium species—can affect systemic immunity. This is important because the state of the immune system influences the body’s ability to fight cancer and also the response to immunotherapies. Preclinical investigations have demonstrated that certain Bifidobacterium strains may help improve responses to immune checkpoint inhibitors in animal models. There has been emerging research looking into discrete strains or formulations of Bifidobacterium longum (sometimes labeled with additional identifiers such as RAPO) that may have unique properties or enhanced effects. |
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 5629- | Bif, | ProBio, | Gut microbiota shapes cancer immunotherapy responses |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:256 Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid